Skip to content

Opening book details…

Can I read Reduced O -GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney on EtoBox?

Reduced O -GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney by Hodrea, Judit; Balogh, Dora B; Hosszu, Adam; Lenart, Lilla; Besztercei, Balazs; Koszegi, Sandor; Sparding, Nadja; Genovese, Federica; Wagner, Laszlo J; Szabó, Attila J; Fekete, Andrea is a Medicine article available to read on EtoBox.

What is Reduced O -GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney about?

Diabetic kidney disease is a worldwide epidemic, and therapies are incomplete. Clinical data suggest that improved renal outcomes by Na^+^-glucose cotransporter 2 inhibitor (SGLT2i) are partly beyond their antihyperglycemic effects; however, the mechanisms are still elusive. Here, we investigated the effect of the SGLT2i dapagliflozin (DAPA) in the prevention of elevated __O__-GlcNAcylation and tubular hypoxia as contributors of renal fibrosis. Type 1 diabetes was induced by streptozotocin in adult male Wistar rats. After the onset of diabetes, rats were treated for 6 wk with DAPA or DAPA combined with losartan (LOS). The effect of hyperglycemia was tested in HK-2 cells kept under normal or high glucose conditions. To test the effect of hypoxia, cells were kept in 1% O~2~ for 2 h. Cells were treated with DAPA or DAPA combined with LOS. DAPA slowed the loss of renal function, mitigated renal tubular injury markers (kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin), and reduced tubulointerstitial fibrosis. DAPA diminished high glucose-induced protein __O__-GlcNAcylation and moderated the tubular response to hypoxia through the hypoxia-inducible factor pathway.

Who reads Reduced O -GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Hodrea, Judit; Balogh, Dora B; Hosszu, Adam; Lenart, Lilla; Besztercei, Balazs; Koszegi, Sandor; Sparding, Nadja; Genovese, Federica; Wagner, Laszlo J; Szabó, Attila J; Fekete, Andrea
Publisher
The American Physiological Society; American Physiological Society (ISSN 0363-6127)
Published
2020
Language
EN
Field
Medicine (Health Sciences)

More by Hodrea, Judit; Balogh, Dora B; Hosszu, Adam; Lenart, Lilla; Besztercei, Balazs; Koszegi, Sandor; Sparding, Nadja; Genovese, Federica; Wagner, Laszlo J; Szabó, Attila J; Fekete, Andrea

Browse all works by Hodrea, Judit; Balogh, Dora B; Hosszu, Adam; Lenart, Lilla; Besztercei, Balazs; Koszegi, Sandor; Sparding, Nadja; Genovese, Federica; Wagner, Laszlo J; Szabó, Attila J; Fekete, Andrea